Overview
Investment firm focused on life sciences and biotechnology ventures.
Founded
1994
Deals ยท 12mo
1
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Breye Therapeutics | Sep 2026Participated | $77 MSeries A | |
VFlow Tech | May 2025Participated | $21 MOther Equity | |
Solu Therapeutics | Apr 2025Participated | $41 MSeries A | |
EarthOptics | Nov 2024Participated | $24 MOther Equity | |
Enlaza Therapeutics | Apr 2024Participated | $100 MSeries A | |
Veralox Therapeutics | Jun 2023Participated | $24 MOther Equity | |
Horizon Quantum Computing | Apr 2023Participated | $18 MSeries A | |
VFlow Tech | Feb 2023Participated | $10 MSeries A | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
NuProbe | Jun 2022Participated | $50 MOther Equity | |
Plexium | Feb 2022Participated | $102 MOther Equity | |
AvengeBio | Jan 2022Participated | $45 MSeries A | |
Breye Therapeutics | Sep 2026Participated | $77 MSeries A | |
VFlow Tech | May 2025Participated | $21 MOther Equity | |
Solu Therapeutics | Apr 2025Participated | $41 MSeries A | |
EarthOptics | Nov 2024Participated | $24 MOther Equity | |
Enlaza Therapeutics | Apr 2024Participated | $100 MSeries A | |
Veralox Therapeutics | Jun 2023Participated | $24 MOther Equity | |
Horizon Quantum Computing | Apr 2023Participated | $18 MSeries A | |
VFlow Tech | Feb 2023Participated | $10 MSeries A | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
NuProbe | Jun 2022Participated | $50 MOther Equity | |
Plexium | Feb 2022Participated | $102 MOther Equity | |
AvengeBio | Jan 2022Participated | $45 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 12 |
| Series B | 0 | 3 |
| Series C+ | 0 | 4 |
| Other Equity | 0 | 6 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '15 | 1 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 1 |
| Apr '17 | 0 |
| May '17 | 1 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 2 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 2 |
| Nov '18 | 2 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 2 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 1 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 1 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 22 |
| Hardware & Robotics | 3 |
| Food & Agriculture | 2 |
| Clean Energy & Sustainability | 2 |
| Space & Frontier Tech | 2 |
| Networks, Cloud & Communication | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 7 |
| $25M-$50M | 4 |
| $50M-$100M | 11 |
| $100M-$250M | 4 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 20 |
| Singapore | 3 |
| Canada | 2 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| New Enterprise Associates | 6 |
| RiverVest Venture Partners | 5 |
| Alexandria Venture Investments | 4 |
| Lundbeckfond Ventures | 4 |
| Novo Holdings | 4 |
| Arix Bioscience | 3 |
| Hatteras Venture Partners | 3 |
| Rock Springs Capital | 3 |
| Sofinnova Ventures | 3 |
| Tekla Capital Management | 3 |
| Adage Capital Management | 2 |
| Amgen Ventures | 2 |
| BDC Capital | 2 |
| BioMed Ventures | 2 |
| Boxer Capital | 2 |
| Cormorant Asset Management | 2 |
| DCVC Bio | 2 |
| Domain Associates | 2 |
| Farallon Capital Management | 2 |
| Fonds de solidarit FTQ | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 1 | 4% |
| Participating | 25 | 96% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 1 | 100% |
Team
CEO
Associate
Partner & Senior Advisor
Venture Partner
Senior Associate, Operations
Principal
Chief Financial Officer
